EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma Cell Leukemia—Clinicopathological Profile from a Tertiary Care Center in Western India

Poornima Manimaran, Varnika Rai, Rahul Ranka, Jyoti Sawhney

South Asian Journal of Cancer · 01.07.2023 · 12 (03) · 280-285

DOI: 10.1055/s-0043-57231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift South Asian Journal of Cancer, erschienen am 01.07.2023. Verfasst von Poornima Manimaran und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Plasma cell leukemia (PCL) is very uncommon and aggressive neoplasm constituting 2 to 4% of all plasma cell dyscrasias. By definition, clonal plasma cells should make up 20% of peripheral blood or have an absolute plasma cell count of 2 × 109 cells/cu.mm. PCL can be primary or secondary. In this study, the clinicohematological features of PCL, and correlation of immunophenotypic profile and conventional therapies with overall survival was analyzed. Materials and Methods This retrospective study involved PCL patients who were diagnosed across a 12-year period, from 2010 to 2021, at a tertiary care center in western India. Clinical, biochemical, peripheral smear, bone marrow aspirate, immunophenotyping, and molecular analysis were performed.

Results

Total 39 PCL patients were included in the study among which 36 were primary PCL patients. Splenomegaly (10/27), hepatomegaly (6/26), and lymphadenopathy (5/23) were noted. At presentation, all patients had anemia (11mg/dl) 10/33 (30.3%) and lytic lesions was noted in 18/26 (69.2%). Immunophenotype of these patients showed CD 38 positivity, CD 138 positivity, CD56 positivity, and CD 117 negativity were 100, 62, 41.6, and 89%, respectively. Overall survival of our patients was 4.1 months and overall survival of patients treated with VTD (bortezomib, thalidomide, dexamethasone) and VCD (bortezomib, cyclophosphamide, dexamethasone) regimen was 3.4 and 4.1 months, respectively, which was not statically significant (p-value 0.816). CD117 and CD56 markers were also not having any prognostic significance (p-value 1.000 and 0.873, respectively).

Conclusion

Because of rarity of the disease, prospective studies are very limited and hence management and outcome of the disease are difficult to analyze. The current treatment protocols have no survival advantage and hence newer therapeutic approach is mandatory to attain better outcome.

Schlagwörter

Stichwörter der Autor:innen

CD117CD56circulating plasma cellsimmature plasma cellsplasma cell leukemia

Autor:innen und Institutionen

  • Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India.
  • Department of Oncopathology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India.

Zitieren

APA

Manimaran, P., Rai, V., Ranka, R., & Sawhney, J. (2023). Plasma Cell Leukemia—Clinicopathological Profile from a Tertiary Care Center in Western India. South Asian Journal of Cancer, 12(03), 280-285. https://doi.org/10.1055/s-0043-57231

Vancouver

Manimaran P, Rai V, Ranka R, Sawhney J. Plasma Cell Leukemia—Clinicopathological Profile from a Tertiary Care Center in Western India. South Asian Journal of Cancer. 2023;12(03):280-285. doi:10.1055/s-0043-57231

BibTeX
@article{Manimaran2023,
  author = {Manimaran, Poornima and Rai, Varnika and Ranka, Rahul and Sawhney, Jyoti},
  title = {Plasma Cell Leukemia—Clinicopathological Profile from a Tertiary Care Center in Western India},
  journal = {South Asian Journal of Cancer},
  year = {2023},
  volume = {12},
  number = {03},
  pages = {280--285},
  doi = {10.1055/s-0043-57231}
}
Kostenlos starten →